Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$129.9 million.

  • SAB Biotherapeutics' Cash from Investing Activities fell 1116705.45% to -$129.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.7 million, marking a year-over-year decrease of 41809.25%. This contributed to the annual value of -$12.0 million for FY2024, which is 773363.04% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Cash from Investing Activities stood at -$129.9 million, which was down 1116705.45% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Cash from Investing Activities peaked at $11.2 million during Q2 2024, and registered a low of -$129.9 million during Q3 2025.
  • In the last 5 years, SAB Biotherapeutics' Cash from Investing Activities had a median value of -$117754.0 in 2022 and averaged -$7.6 million.
  • Data for SAB Biotherapeutics' Cash from Investing Activities shows a peak YoY increase of 4955696.09% (in 2024) and a maximum YoY decrease of 14712632.39% (in 2024) over the last 5 years.
  • Over the past 5 years, SAB Biotherapeutics' Cash from Investing Activities (Quarter) stood at -$2.4 million in 2021, then soared by 95.01% to -$117754.0 in 2022, then surged by 42.37% to -$67864.0 in 2023, then skyrocketed by 13849.21% to $9.3 million in 2024, then plummeted by 1491.84% to -$129.9 million in 2025.
  • Its last three reported values are -$129.9 million in Q3 2025, $5.2 million for Q2 2025, and $4.7 million during Q1 2025.